Takeda joins malaria and TB drug discovery consortium, WIPO Re:Search

Takeda is to participate in WIPO Re:Search, a consortium to accelerate research and development of new drugs, vaccines, and diagnostics for malaria and tuberculosis (TB).

WIPO Re:Search’s aim is to advance product development through greater collaboration while making concrete contributions to strengthen the foundations of healthcare in developing countries.

“Takeda’s participation in the consortium demonstrates our commitment to supporting better access to medicines for people around the world, including those in emerging markets and developing counties,” said Isabel Torres, Director, Access to Medicines, Takeda. “We will continue our efforts to contribute to global health through WIPO Re:Search, together with a number of other Access to Medicines programmes such as the Global Health Innovative Technology Fund.”

WIPO Re:Search promotes research to develop innovative treatments

WIPO Re:Search was established in 2011 by the World Intellectual Property Organisation (WIPO) in collaboration with BIO Ventures for Global Health (BVGH) and with the active participation of leading pharmaceutical companies and other renowned public sector research organisations. Through a public database managed by WIPO, members of the consortium, including the US National Institutes of Health (NIH), provide their intellectual property assets and resources, such as compounds and expertise, under royalty-free licenses. Non-profit organisations and other qualified research institutions will gain access to these assets for the research and development of new drugs, vaccines, and diagnostics. By sharing assets and relevant information via the database, the consortium promotes research to develop innovative treatments for patients.

Based on the needs of WIPO Re:Search members, Takeda said that it is working with BVGH to evaluate and determine potential assets and future contributions from Takeda to the consortium.